Accolade, Inc. ACCD
We take great care to ensure that the data presented and summarized in this overview for Accolade, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACCD
View all-
Black Rock Inc. New York, NY6.16MShares$43.2 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.66MShares$32.7 Million0.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.18MShares$29.4 Million0.0% of portfolio
-
Ah Equity Partners Iv (Parallel), L.L.C. Menlo Park, CA3.78MShares$26.5 Million88.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.48MShares$24.4 Million0.29% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.09MShares$21.7 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA2.98MShares$20.9 Million0.03% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.28MShares$16 Million0.01% of portfolio
-
Fairman Group, LLC Chesterbrook, PA1.8MShares$12.7 Million5.07% of portfolio
-
Nikko Asset Management Americas, Inc.1.77MShares$12.4 Million0.07% of portfolio
Latest Institutional Activity in ACCD
Top Purchases
Top Sells
About ACCD
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Transactions at ACCD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 08
2025
|
Rajeev Singh Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
651,619
-100.0%
|
$4,561,333
$7.03 P/Share
|
|
Apr 08
2025
|
Rajeev Singh Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
831,955
-100.0%
|
$5,823,685
$7.03 P/Share
|
|
Apr 08
2025
|
Peter S Klein |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,329
-100.0%
|
$198,303
$7.03 P/Share
|
|
Apr 08
2025
|
Patricia L Wadors |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,759
-100.0%
|
$194,313
$7.03 P/Share
|
|
Apr 08
2025
|
Cindy Kent |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,360
-100.0%
|
$9,520
$7.03 P/Share
|
|
Apr 08
2025
|
Cindy Kent |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,602
-100.0%
|
$74,214
$7.03 P/Share
|
|
Apr 08
2025
|
Jeffrey S Brodsky |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,810
-100.0%
|
$327,670
$7.03 P/Share
|
|
Apr 08
2025
|
Jeffrey D Jordan |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,398,708
-100.0%
|
$37,790,956
$7.03 P/Share
|
|
Apr 08
2025
|
Jeffrey D Jordan |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,759
-100.0%
|
$194,313
$7.03 P/Share
|
|
Apr 08
2025
|
Elizabeth G Nabel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
41,982
-100.0%
|
$293,874
$7.03 P/Share
|
|
Apr 08
2025
|
Richard Eskew EVP General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
66,191
-100.0%
|
$463,337
$7.03 P/Share
|
|
Apr 08
2025
|
Stephen H. Barnes Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
306,874
-100.0%
|
$2,148,118
$7.03 P/Share
|
|
Apr 08
2025
|
Michael W Hilton |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
195,042
-100.0%
|
$1,365,294
$7.03 P/Share
|
|
Apr 08
2025
|
Michael W Hilton |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,946
-100.0%
|
$1,056,622
$7.03 P/Share
|
|
Apr 08
2025
|
Robert N Cavanaugh President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
222,216
-100.0%
|
$1,555,512
$7.03 P/Share
|
|
Apr 02
2025
|
Stephen H. Barnes Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
431
-0.14%
|
$2,586
$6.99 P/Share
|
|
Apr 02
2025
|
Richard Eskew EVP General Counsel |
SELL
Open market or private sale
|
Direct |
378
-0.57%
|
$2,268
$6.99 P/Share
|
|
Apr 02
2025
|
Rajeev Singh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
922
-0.11%
|
$5,532
$6.99 P/Share
|
|
Apr 02
2025
|
Robert N Cavanaugh President |
SELL
Open market or private sale
|
Direct |
550
-0.25%
|
$3,300
$6.99 P/Share
|
|
Apr 01
2025
|
Stephen H. Barnes Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,568
+0.51%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 495K shares |
|---|---|
| Grant, award, or other acquisition | 13.9K shares |
| Sale (or disposition) back to the issuer | 8.01M shares |
|---|---|
| Open market or private sale | 116K shares |